UNSPSC 51333503: Halopemide

This classification denotes an antipsychotic agent with the molecular formula C21H22ClFN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65Q28TV0ZY, chemically known as r 34,301 but generally known as halopemide, which bears US NIH Compound Identifier 65490. European Medicines Agency schedules Halopemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08003MIG. The term HALOPEMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18).

UNSPSC 51333503 Halopemide is a Commodity code for pharmaceutical products, but the recent state and local contract opportunities tagged under it reflect a broader pattern of government procurement for generic pharmaceuticals, over-the-counter products, and naloxone-related health interventions rather than the specific drug halopemide. State and local governments soliciting under this code are acquiring multi-source generic pharmaceuticals, OTC products, and emergency-response medications through competitive bidding and cooperative purchasing mechanisms. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The procurement spans direct purchase of specific quantities for immediate deployment—such as Seminole County's order of 1,900 units of naloxone annually—as well as framework agreements and manufacturer contracts that supply wholesalers serving multiple government jurisdictions and healthcare facilities. Vendors must demonstrate compliance with Drug Supply Chain Security Act (DSCSA) requirements, current Good Manufacturing Practices (cGMP) certification, FDA registration, and established relationships with authorized pharmaceutical wholesalers.

Recent activity centers in Florida and Minnesota-led multistate purchasing. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023, through quarterly deliveries to the Seminole County Community Health Building in Sanford. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with contracts effective July 1, 2026. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment programs. Contracts typically span two years with optional renewals; vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and comply with federal funding requirements including the Clean Air Act and Federal Water Pollution Control Act when applicable.